Steven M Kornblau
Overview
Explore the profile of Steven M Kornblau including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
184
Citations
7882
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Escherich C, Moriyama T, Li Z, Hsiao Y, Hsiao Y, Yang W, et al.
Blood
. 2025 Jan;
145(11):1182-1194.
PMID: 39791601
Inotuzumab ozogamicin (InO) is an antibody-calicheamicin conjugate with striking efficacy in B-cell acute lymphoblastic leukemia (B-ALL). However, there is wide interpatient variability in treatment response, and the genetic basis of...
2.
Hoff F, Sriraja L, Qiu Y, Jenkins G, Teachey D, Wood B, et al.
Cancers (Basel)
. 2025 Jan;
16(24).
PMID: 39766140
Background: The 5-year overall survival (OS) rates of T-cell lymphocytic leukemia (T-ALL) are better for children (>90%) compared to adults (~57%). The early T-cell precursor (ETP) T-ALL subtype is prognostically...
3.
Chakraborty S, Morganti C, Pena B, Zhang H, Verma D, Zaldana K, et al.
bioRxiv
. 2024 Aug;
PMID: 39211137
Statement Of Purpose: Five-year survival from AML is dismal at 30%. Our prior research demonstrated STAT3 over-expression in AML HSPC's to be associated with inferior survival. We now explore STAT3...
4.
Yoshimura S, Li Z, Gocho Y, Yang W, Crews K, Lee S, et al.
J Clin Oncol
. 2024 Aug;
42(29):3478-3490.
PMID: 39102629
Purpose: Acute lymphoblastic leukemia (ALL) can occur across all age groups, with a strikingly higher cure rate in children compared with adults. However, the pharmacological basis of age-related differences in...
5.
Kimura S, Park C, Montefiori L, Iacobucci I, Polonen P, Gao Q, et al.
Cancer Discov
. 2024 Jun;
14(10):1838-1859.
PMID: 38916500
Acute lymphoblastic leukemia expressing the gamma delta T-cell receptor (γδ T-ALL) is a poorly understood disease. We studied 200 children with γδ T-ALL from 13 clinical study groups to understand...
6.
Narayanan N, Marvin-Peek J, Abouelnaaj M, Majid D, Wang B, Brown B, et al.
J Proteome Res
. 2024 Jun;
23(7):2495-2504.
PMID: 38829961
Asparaginase-based therapy is a cornerstone in acute lymphoblastic leukemia (ALL) treatment, capitalizing on the methylation status of the asparagine synthetase (ASNS) gene, which renders ALL cells reliant on extracellular asparagine....
7.
Bhattarai K, Mobley R, Barnett K, Ferguson D, Hansen B, Diedrich J, et al.
Nat Commun
. 2024 May;
15(1):3681.
PMID: 38693155
Defining genetic factors impacting chemotherapy failure can help to better predict response and identify drug resistance mechanisms. However, there is limited understanding of the contribution of inherited noncoding genetic variation...
8.
van Dijk A, Hoff F, Qiu Y, Hubner S, Go R, Ruvolo V, et al.
Cancers (Basel)
. 2024 Apr;
16(8).
PMID: 38672531
The addition of the proteasome inhibitor bortezomib to standard chemotherapy did not improve survival in pediatric acute myeloid leukemia (AML) when all patients were analyzed as a group in the...
9.
Huang X, Li Y, Zhang J, Yan L, Zhao H, Ding L, et al.
Cancer Cell
. 2024 Apr;
42(4):552-567.e6.
PMID: 38593781
Leukemia can arise at various stages of the hematopoietic differentiation hierarchy, but the impact of developmental arrest on drug sensitivity is unclear. Applying network-based analyses to single-cell transcriptomes of human...
10.
Bose P, Masarova L, Pemmaraju N, Bledsoe S, Daver N, Jabbour E, et al.
Haematologica
. 2024 Apr;
109(8):2660-2664.
PMID: 38572554
No abstract available.